OrthoPediatrics preliminary Q3 revenue $61.2M, consensus $63.63M

“In the third quarter, we faced incremental headwinds late in September, largely driven by delayed 7D capital sales and headwinds within the Latin and South America segment of our business, which contributed to a revenue shortfall relative to our expectations. While still important parts of our business plan, order timing across these segments is difficult to forecast and will continue to be variable. We believe it is prudent to reflect minimal sales growth from these segments for the fourth quarter and into the future,” commented David Bailey, President and CEO of OrthoPediatrics (KIDS). “We are reaffirming a steadfast commitment to driving revenue growth that expands profitability and supports achieving cash flow break-even in 2026. Our comprehensive product portfolio, including OPSB braces and services, combined with the breadth of our commercial footprint uniquely positions OrthoPediatrics as the undisputed leader in pediatric orthopedics, will enable the organization to execute on our mission to continue to help more kids every year.”